RBM15 and metabolic dysfunction-associated steatotic liver disease: Because m6A modification was involved in the occurrence of NAFLD rather than the progression, m6A regulators like RBM15 and YTH family might serve as the potential targets for the prevention and treatment of NAFLD in obese people.